Stifel Financial
RNXT icon

Stifel Financial’s RenovoRx RNXT Stock Holding History

Stifel Financial’s Portfolio RNXT Stock Details RNXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-31,678
Closed -$64K – 3368
2022
Q3 		$64K Hold
31,678
– – ﹤0.01% 3163
2022
Q2 		$63K Buy
31,678
+2,535
+9% +$5.18K ﹤0.01% 3208
2022
Q1 		$85K Buy
+29,143
New +$102K ﹤0.01% 3269

Other funds holding RNXT

BOTW
Bank of the West Monterey Park, California $851M AUM 15.39% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return
ACA
Affinity Capital Advisors Berkeley, California $810M AUM 24.85% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Stifel Financial's RNXT Position: Q4 2022 in Review

Stifel Financial sold out of RenovoRx (RNXT) in Q4 2022, closing a stake of 31,678 shares — an estimated $64K sold.

Stifel Financial first reported a position in RNXT in Q1 2022 and held it in 3 quarters. The position peaked at $85K in Q1 2022. 11 funds tracked by Wall St. Rank hold RNXT as of Q4 2022.

  • Stifel Financial reported no remaining RenovoRx position as of Q4 2022 after selling out during the quarter.
  • Stifel Financial sold 31,678 RenovoRx shares in Q4 2022, an estimated $64K.
  • Stifel Financial first reported a position in RenovoRx in Q1 2022 and held it in 3 quarters.
  • Stifel Financial's RenovoRx position peaked at $85K in Q1 2022.
  • 11 funds tracked by Wall St. Rank held RenovoRx as of Q4 2022.

Based on Stifel Financial's 13F filing for Q4 2022, filed 13 Feb 2023.